source
- Eli Lilly partners with AI startup Profluent to develop next-generation gene editorsEli Lilly announced a collaboration with AI-focused biotech Profluent to create advanced gene-editing tools that could insert whole genes into patients. The partnership is intended to move beyond…
- Incyte reports positive Phase 3 results for povorcitinib in nonsegmental vitiligo, plans FDA filingIncyte announced that its oral JAK1 inhibitor povorcitinib achieved positive outcomes in two Phase 3 trials targeting nonsegmental vitiligo. The studies met their primary endpoints, demonstrating…